IBJNews

Lilly to cut 170 manufacturing jobs by year's end

Back to TopCommentsE-mailPrintBookmark and Share

Eli Lilly and Co. will cut 170 jobs—mostly in Indianapolis—from its manufacturing and quality division by the end of the year as it continues its efforts to slim down before losing revenue from patent expirations on its bestselling drugs.

The Indianapolis-based drugmaker’s latest move will cut nearly 5 percent of its 3,600-person manufacturing work force in the United States.

It has factories in Indianapolis and Clinton, Ind., where the cuts will take place, affecting manufacturing support workers, wrote company spokeswoman Janice Chavers in an e-mail.

To reach the 170-job target, Lilly will ask for voluntary departures, but it will also eliminate the jobs of others involuntarily. Some jobs have already been eliminated through attrition.

Chavers did not specify how many manufacturing employees would have their jobs eliminated involuntarily. But those that do will be eligible to apply for open jobs within Lilly, including some that might be vacated by those taking a voluntary buyout. All employees who depart will be offered a separation package, which is based on pay grade and time served at Lilly.

Lilly has announced nearly 2,000 job cuts toward its goal of 5,500 cuts, which the company set in September. The company is also trying to eliminate $1 billion in annual expenses by the end of 2011. At that time, it hopes to have a worldwide staff of about 35,000. It currently employs 12,400 in Indiana.

Job cuts so far have come in nearly every area of the company, including sales, marketing, communications, information technology and manufacturing.

Last year, Lilly sold off its Tippecanoe manufacturing facility to Germany-based Evonik Industries AG, which affected 700 workers. Nearly all were offered jobs with Evonik.

Lilly’s bestselling drug, the antipsychotic Zyprexa, will face competition from cheap generic copies when its U.S. and European patents expire in October 2011. In the following three years, Lilly will watch patents expire on four other bestselling drugs, threatening to steal nearly 60 percent of its $22 billion in annual revenue.

Internally, Lilly calls that time span “Years YZ.”

“All this is being done so that the organization can right-size ahead of YZ,” Chavers wrote in an e-mail. “The organization is continually evaluating how it can operate more efficiently and more productively, and adjusts operations accordingly.”
 

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. The $104K to CRC would go toward debts service on $486M of existing debt they already have from other things outside this project. Keystone buys the bonds for 3.8M from CRC, and CRC in turn pays for the parking and site work, and some time later CRC buys them back (with interest) from the projected annual property tax revenue from the entire TIF district (est. $415K / yr. from just this property, plus more from all the other property in the TIF district), which in theory would be about a 10-year term, give-or-take. CRC is basically betting on the future, that property values will increase, driving up the tax revenue to the limit of the annual increase cap on commercial property (I think that's 3%). It should be noted that Keystone can't print money (unlike the Federal Treasury) so commercial property tax can only come from consumers, in this case the apartment renters and consumers of the goods and services offered by the ground floor retailers, and employees in the form of lower non-mandatory compensation items, such as bonuses, benefits, 401K match, etc.

  2. $3B would hurt Lilly's bottom line if there were no insurance or Indemnity Agreement, but there is no way that large an award will be upheld on appeal. What's surprising is that the trial judge refused to reduce it. She must have thought there was evidence of a flagrant, unconscionable coverup and wanted to send a message.

  3. As a self-employed individual, I always saw outrageous price increases every year in a health insurance plan with preexisting condition costs -- something most employed groups never had to worry about. With spouse, I saw ALL Indiana "free market answer" plans' premiums raise 25%-45% each year.

  4. It's not who you chose to build it's how they build it. Architects and engineers decide how and what to use to build. builders just do the work. Architects & engineers still think the tarp over the escalators out at airport will hold for third time when it snows, ice storms.

  5. http://www.abcactionnews.com/news/duke-energy-customers-angry-about-money-for-nothing

ADVERTISEMENT